Count | |
| 5 | |
| 2 | |
| 7 | |
| 23 | |
| 3 | |
| 2 | |
| 5 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 13 | |
| 1 | |
| 2 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 5 | |
| 2 | |
| 1 | |
| 1 | |
| 7 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 3 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
Gold/administration & dosage/*adverse effects/*diagnostic use/immunology | 1 |
Gold Colloid/*administration & dosage/chemical synthesis/pharmacokinetics | 1 |
Antirheumatic Agents, Gold/administration & dosage/*adverse effects | 1 |
| 29 | |
| 3 | |
| 6 | |
| 1 | |
| 255 | |
| 2 | |
| 72 | |
| 14 | |
| 2 | |
| 3 | |
| 202 | |
| 1 | |
| 55 | |
| 1 | |
| 2 | |
| 4 | |
| 5 | |
| 2 | |
| 1 | |
| 16 | |
| 7 | |
| 1 | |
| 2 | |
| 3 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 9 | |
| 4 | |
| 5 | |
| 2 | |
| 3 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 2 | |
| 7 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 2 | |